Skip to main content

Table 1 Clinical features of the included patients with PDA

From: Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma

Variable Before PSM After PSM
None (n = 3770) PTR (n = 552) P value None (n = 720) PTR (n = 240) P value
Age (years) 66.7 ± 11.3 64.6 ± 10.5 < 0.001 67.4 ± 11.1 67.2 ± 10.2 0.777
Sex    0.510    0.911
 Female 1887 (50.1%) 268 (48.6%)   361 (50.1%) 122 (50.8%)  
 Male 1883 (49.9%) 284 (51.4%)   359 (49.9%) 118 (49.2%)  
Race    0.528    0.161
 White 2968 (78.7%) 445 (80.6%)   563 (78.2%) 197 (82.1%)  
 Black 463 (12.3%) 59 (10.7%)   93 (12.9%) 20 (8.3%)  
 Other 339 (9.0%) 48 (8.7%)   64 (8.9%) 23 (9.6%)  
Primary tumor site in pancreas    < 0.001    0.463
 Head 2672 (70.9%) 438 (79.3%)   501 (69.6%) 173 (72.1%)  
 Body and tail 1080 (28.6%) 116 (19.2%)   219 (30.4%) 67 (27.9%)  
Tumor size (mm) 41.0 ± 15.4 38.5 ± 16.3 < 0.001 44.9 ± 16.7 45.6 ± 18.6 0.558
Tumor differentiation    < 0.001    0.197
 I 178 (4.7%) 52 (9.4%)   57 (7.9%) 17 (7.1%)  
 II 402 (10.7%) 223 (40.4%)   153 (21.2%) 56 (23.3%)  
 III 421 (11.2%) 163 (29.5%)   168 (23.3%) 53 (22.1%)  
 IV 26 (0.7%) 3 (0.5%)   1 (0.1%) 3 (1.2%)  
Chemotherapy    0.272    0.228
 No/unknown 2960 (78.5%) 422 (76.4%)   608 (84.4%) 194 (80.8%)  
 Yes 810 (21.5%) 130 (23.6%)   112 (15.6%) 46 (19.2%)  
  1. Data are shown as mean ± SD or n (%). PTR, primary tumor resection. Tumor differentiation: I, well-differentiated; II, moderate- differentiated; III, poor-differentiated; IV, un-differentiated